BioSpace News Archive

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be attending the American Headache Society’s 2020 Scottsdale Headache Symposium® as a Gold Level Sponsor. Due to the COVID-19 pandemic

Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes.

HealthCore, an outcomes research company of Anthem, Inc., is managing a new study to help understand and combat the pediatric public health emergency arising from the COVID-19 pandemic.

Grifols has been recognized among the world’s most sustainable companies by the Dow Jones Sustainability Index, the largest global sustainability index and an international benchmark for socially responsible investors.

Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that the first cohort of its Phase 1 clinical study of REVTx‑99 in healthy volunteers (RVL‑NHV01 study) has completed dosing. Eight study participants were dosed with REVTx-9

Spectrum Antimicrobials, Inc., a subsidiary of Collidion, Inc. announces the development of a novel antiviral drug candidate designed to treat pulmonary infections.

Simplify Medical, Inc., maker of the Simplify® Cervical Artificial Disc, announced that David Hovda, President and Chief Executive Officer, will present at the 2020 Canaccord Genuity Virtual Medical Technologies & Diagnostics Forum and invites investors to participate via the conference webcast.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox’s first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications. Unavoidable delays have been incurred in this project mainly due to the very lon

Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~ ~ No Clinical Safety or Efficacy Issues Identified ; No Additional Studies Required for PEDMARK™ ~ ~ The Company Has Approximately $33 Million in Cash and No Outstanding Debt ~